← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Immunomedics, Inc.
Morris Plains, NJ
$13,278,111
Total funding
24
Grants
Funding over time
peak $2.8M · FY2005–13$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
Funding mix
By agency
NIH$12,016,433 · 23
DOD$1,261,678 · 1
By mechanism
R44$9,575,215 · 8
R43$2,250,075 · 14
—$1,261,678 · 1
R41$191,143 · 1
Investigators at Immunomedics, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
Largest grants
Development of an interferon-alpha-veltuzumab conjugate for CD20-targeted therapy$2,283,892
R44 · FY2011 · CA
CD74 IMMUNOTHERAPY OF SYSTEMIC LUPUS ERYTHEMATOSUS$1,261,678
· FY2013 · Department of the Army
Combined radio- and immunotherapy of aggressive NHL$1,137,221
R44 · FY2013 · CA
Combined radio- and immunotherapy of aggressive NHL$859,792
R44 · FY2009 · CA
MAb-based targeted chemotherapy of lung cancer$724,653
R44 · FY2008 · CA
F-18 Labeled Peptides for Pretargeted PET Imaging of Pancreatic Cancer$605,718
R44 · FY2009 · RR
Development of an interferon-alpha-veltuzumab conjugate for CD20-targeted therapy$544,981
R44 · FY2010 · CA
Dock and Lock: Novel Protein Engineering$520,817
R44 · FY2008 · CA
F-18 Labeled Peptides for Pretargeted PET Imaging of Pancreatic Cancer$517,243
R44 · FY2010 · RR
An anti-CD74 MAb-drug conjugate for B-cell malignancies$492,190
R44 · FY2008 · CA
RADIOIMMUNOTHERAPY USING BISPECIFIC ANTIBODIES$442,937
R44 · FY2000 · CA
Dock and Lock: Novel Protein Engineering$366,809
R44 · FY2009 · CA
An anti-CD74 MAb-drug conjugate for B-cell malignancies$309,824
R44 · FY2009 · CA
Bispecific antibody pretargeted immunoPET of prostate cancer$276,833
R43 · FY2012 · CA
IMPROVED RADIOIODINATION METHODS FOR RADIOIMMUNOTHERAPY$275,478
R44 · FY2000 · CA
RADIOIMMUNOTHERAPY USING BISPECIFIC ANTIBODIES$253,958
R44 · FY2001 · CA
MAb-based targeted chemotherapy of lung cancer$239,702
R44 · FY2009 · CA
Humanized Anti-Trop2-SN-38 Conjugate For Advanced Pancreatic Cancer$227,025
R43 · FY2012 · CA
Localization of Pancreatic Cancer by a Pretargeted 18F-Hapten-Peptide$213,982
R43 · FY2013 · CA
TROP-2-targeted tetrameric ranpirnase for therapy of triple-negative breast cance$200,782
R43 · FY2013 · CA